Literature DB >> 16884362

Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.

N Jandu1, M Richardson, G Singh, H Hirte, M W C Hatton.   

Abstract

Ovarian cancer ascites fluid (OCAF) displayed an antiangiogenic property in a chick chorioallantoic membrane (CAM) assay. This property was attributed in part to angiostatin although angiostatin-free OCAF retained a net antiangiogenic property. Recently, immunopurified fibrin(ogen) degradation products (FDPs) from malignant effusions of VX2 tumor-burdened rabbits exhibited antiangiogenic activity on the CAM. We questioned whether the FDPs of OCAF were also antiangiogenic. FDPs were immunopurified from individual OCAF samples, characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis /western blots, enzyme-linked immunosorbent assays, and CAM assays. FDPs of OCAFs consisted of soluble high molecular weight (MW) fragments (>200 kd; approximately 40% of total FDPs), D-dimer (approximately 180 kd; approximately 37%), fragment D (approximately 90 kd; approximately 15%), and fragment E (approximately 50 kd; approximately 8%); intact fibrinogen was absent. When applied to CAM surfaces (0.5-1.6 mg/10 mL), purified FDPs significantly reduced the area of chorionic capillaries from 90% (in controls) to 47% over a 48-h period; from CAM sections, capillary density was reduced from 60% (controls) to 26%. FDPs prepared from fibrinogen displayed a similar antiangiogenic effect. Further digestion of OCAF FDPs by human plasmin caused degradation of high MW fragments, releasing additional D-dimer, fragment D, and fragment E. Of the fibrinogen-related components, OCAF contained only soluble FDPs (including incompletely digested fibrin fragments). Collectively, these FDPs contributed to the net antiangiogenic property of ascites fluid.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884362     DOI: 10.1111/j.1525-1438.2006.00624.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  11 in total

1.  Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences.

Authors:  Aya Mizrahi; Abraham Hochberg; Smadar Amiur; Jennifer Gallula; Imad Matouk; Tatiana Birman; Tally Levy; Sorin Ladimir; Patricia Ohana
Journal:  Int J Clin Exp Med       Date:  2010-09-21

2.  Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.

Authors:  Heming Li; Tong Zhao; Xuening Ji; Shanshan Liang; Zhe Wang; Yulong Yang; Jiajun Yin; Ruoyu Wang
Journal:  Tumour Biol       Date:  2015-10-09

3.  Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model.

Authors:  Liliane Meunier; Marie-Line Puiffe; Cécile Le Page; Abdelali Filali-Mouhim; Mario Chevrette; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

Review 4.  Friend and foe: the regulation network of ascites components in ovarian cancer progression.

Authors:  Zhe Geng; Xinxing Pan; Juan Xu; Xuemei Jia
Journal:  J Cell Commun Signal       Date:  2022-10-13       Impact factor: 5.908

5.  Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer.

Authors:  Marie-Line Puiffe; Cécile Le Page; Abdelali Filali-Mouhim; Magdalena Zietarska; Véronique Ouellet; Patricia N Tonin; Mario Chevrette; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Neoplasia       Date:  2007-10       Impact factor: 5.715

6.  Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells.

Authors:  Marie Cohen; Sandra Pierredon; Christine Wuillemin; Florence Delie; Patrick Petignat
Journal:  Oncoscience       Date:  2014-04-30

7.  Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation.

Authors:  Shun-Jun Fu; Fei Ji; Ming Han; Mao-Gen Chen; Xiao-Ping Wang; Wei-Qiang Ju; Qiang Zhao; Lin-Wei Wu; Qing-Qi Ren; Zhi-Yong Guo; Dong-Ping Wang; Xiao-Feng Zhu; Yi Ma; Xiao-Shun He
Journal:  Oncotarget       Date:  2017-01-17

Review 8.  The untapped potential of ascites in ovarian cancer research and treatment.

Authors:  Caroline Elizabeth Ford; Bonnita Werner; Neville Frederick Hacker; Kristina Warton
Journal:  Br J Cancer       Date:  2020-05-08       Impact factor: 7.640

9.  Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences.

Authors:  Aya Mizrahi; Abraham Czerniak; Tally Levy; Smadar Amiur; Jennifer Gallula; Imad Matouk; Rasha Abu-lail; Vladimir Sorin; Tatiana Birman; Nathan de Groot; Abraham Hochberg; Patricia Ohana
Journal:  J Transl Med       Date:  2009-08-06       Impact factor: 5.531

10.  The bright side of ascites in ovarian cancer.

Authors:  Marie Cohen; Patrick Petignat
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.